{"id":"risankizumab-sc","safety":{"commonSideEffects":[{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"IL-23 is a key driver of inflammatory responses in immune-mediated diseases. By inhibiting IL-23 signaling, risankizumab reduces the differentiation and activation of pathogenic T cells and innate lymphoid cells, thereby suppressing chronic inflammation. This mechanism is particularly effective in diseases driven by IL-23-dependent immune responses.","oneSentence":"Risankizumab is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway by binding to the p19 subunit of IL-23.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:34.330Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT05995353","phase":"PHASE3","title":"A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-12-11","conditions":"Crohn's Disease","enrollment":110},{"nctId":"NCT06548542","phase":"PHASE2","title":"Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-09-04","conditions":"Crohn's Disease","enrollment":540},{"nctId":"NCT06880744","phase":"PHASE3","title":"A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-06-17","conditions":"Ulcerative Colitis","enrollment":530},{"nctId":"NCT07466550","phase":"PHASE1","title":"A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2026-03-08","conditions":"Healthy Volunteer","enrollment":60},{"nctId":"NCT06641089","phase":"PHASE3","title":"Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response","status":"RECRUITING","sponsor":"MoonLake Immunotherapeutics AG","startDate":"2024-10-15","conditions":"Arthritis, Psoriatic","enrollment":600},{"nctId":"NCT06346288","phase":"PHASE4","title":"A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-04-24","conditions":"Inflammatory Bowel Disease","enrollment":10},{"nctId":"NCT06333860","phase":"PHASE4","title":"A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2024-05-10","conditions":"Moderate Plaque Psoriasis","enrollment":393},{"nctId":"NCT06100744","phase":"PHASE3","title":"A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-07-08","conditions":"Juvenile Psoriatic Arthritis","enrollment":40},{"nctId":"NCT07071519","phase":"PHASE3","title":"A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-28","conditions":"Ulcerative Colitis","enrollment":120},{"nctId":"NCT07007091","phase":"PHASE1","title":"A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2025-06-12","conditions":"Healthy Volunteers","enrollment":260},{"nctId":"NCT03398135","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-08-28","conditions":"Ulcerative Colitis (UC)","enrollment":1242},{"nctId":"NCT06946524","phase":"PHASE1","title":"A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2025-05-08","conditions":"Healthy Volunteers","enrollment":59},{"nctId":"NCT06865105","phase":"PHASE2","title":"Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-04-11","conditions":"Psoriatic Arthritis","enrollment":120},{"nctId":"NCT06063967","phase":"PHASE3","title":"A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-11-15","conditions":"Crohn's Disease","enrollment":289},{"nctId":"NCT03671148","phase":"PHASE3","title":"A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2019-03-07","conditions":"Psoriatic Arthritis (PsA)","enrollment":444},{"nctId":"NCT03105102","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-04-09","conditions":"Crohn's Disease","enrollment":1336},{"nctId":"NCT04524611","phase":"PHASE3","title":"Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-09-30","conditions":"Crohn's Disease (CD)","enrollment":527},{"nctId":"NCT04862286","phase":"PHASE3","title":"Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2021-07-24","conditions":"Psoriasis","enrollment":132},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT06487572","phase":"PHASE1","title":"A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2024-07-23","conditions":"Healthy Volunteers","enrollment":60},{"nctId":"NCT03398148","phase":"PHASE2, PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-03-07","conditions":"Ulcerative Colitis (UC)","enrollment":1558},{"nctId":"NCT05169593","phase":"PHASE4","title":"Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2022-09-08","conditions":"Crohn Disease","enrollment":292},{"nctId":"NCT06298188","phase":"NA","title":"Risankizumab in Children With Crohn's Disease (RisaKids)","status":"RECRUITING","sponsor":"Shaare Zedek Medical Center","startDate":"2024-10-31","conditions":"Crohn Disease","enrollment":90},{"nctId":"NCT04713592","phase":"PHASE3","title":"Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-02-26","conditions":"Psoriasis","enrollment":174},{"nctId":"NCT04908475","phase":"PHASE4","title":"Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-06-09","conditions":"Psoriasis","enrollment":352},{"nctId":"NCT04102007","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-11-12","conditions":"Plaque Psoriasis","enrollment":244},{"nctId":"NCT04451720","phase":"PHASE3","title":"Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-07-20","conditions":"Palmoplantar Pustulosis (PPP)","enrollment":119},{"nctId":"NCT03219437","phase":"PHASE3","title":"A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-07-30","conditions":"Psoriasis","enrollment":104},{"nctId":"NCT03926169","phase":"PHASE2","title":"A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-06-03","conditions":"Hidradenitis Suppurativa","enrollment":243},{"nctId":"NCT05083078","phase":"PHASE1","title":"A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-11-04","conditions":"Arthritis, Psoriatic, Healthy","enrollment":11},{"nctId":"NCT03105128","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-10","conditions":"Crohn's Disease","enrollment":931},{"nctId":"NCT03104413","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-12-18","conditions":"Crohn's Disease","enrollment":618},{"nctId":"NCT05283694","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-09-11","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT05283681","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-04-02","conditions":"Healthy Volunteers","enrollment":226},{"nctId":"NCT05268068","phase":"PHASE1","title":"A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-06-27","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT03706040","phase":"PHASE2","title":"A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-12-27","conditions":"Dermatitis","enrollment":172},{"nctId":"NCT02684357","phase":"PHASE3","title":"BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":577},{"nctId":"NCT02694523","phase":"PHASE3","title":"BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-03","conditions":"Psoriasis","enrollment":684},{"nctId":"NCT02684370","phase":"PHASE3","title":"BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02","conditions":"Psoriasis","enrollment":560},{"nctId":"NCT03478787","phase":"PHASE3","title":"Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-05-08","conditions":"Psoriasis","enrollment":327},{"nctId":"NCT03875508","phase":"PHASE3","title":"A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-06-04","conditions":"Psoriasis","enrollment":108},{"nctId":"NCT03875482","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-05-13","conditions":"Psoriasis","enrollment":157},{"nctId":"NCT03518047","phase":"PHASE3","title":"Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation","status":"COMPLETED","sponsor":"AbbVie","startDate":"2018-07-19","conditions":"Psoriasis","enrollment":50},{"nctId":"NCT02513459","phase":"PHASE2","title":"A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-09-16","conditions":"Crohn Disease","enrollment":65},{"nctId":"NCT02203851","phase":"PHASE2","title":"Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-11-20","conditions":"Psoriasis","enrollment":110},{"nctId":"NCT03255382","phase":"PHASE3","title":"A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-08-22","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT02047110","phase":"PHASE2","title":"BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01-28","conditions":"Ankylosing Spondylitis (AS)","enrollment":159},{"nctId":"NCT02719171","phase":"PHASE2","title":"BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-04","conditions":"Arthritis, Psoriatic","enrollment":185},{"nctId":"NCT03000075","phase":"PHASE2","title":"BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-12-02","conditions":"Psoriasis","enrollment":182},{"nctId":"NCT02031276","phase":"PHASE2","title":"Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-02","conditions":"Crohn Disease","enrollment":121},{"nctId":"NCT02596217","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-08","conditions":"Healthy","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABBV-066 BI 655066","SKYRIZI","BI 655066","ABBV-066"],"phase":"phase_3","status":"active","brandName":"risankizumab SC","genericName":"risankizumab SC","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risankizumab is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway by binding to the p19 subunit of IL-23. Used for Moderate to severe plaque psoriasis, Crohn's disease, Ulcerative colitis.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2019-04-26T00:00:00.000Z","mah":"AbbVie Deutschland GmbH & Co. KG","brand_name_local":"Skyrizi","application_number":"EMEA/H/C/004759"},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Skyrizi","application_number":"Skyrizi"}],"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}